





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification⁶ : A61K 31/395, 31/495, C07D 471/04, 471/14, 487/04, 487/14</p>	<p>A1</p>	<p>(11) International Publication Number: WO 98/17274 (43) International Publication Date: 30 April 1998 (30.04.98)</p>
<p>(21) International Application Number: PCT/US97/18682 (22) International Filing Date: 20 October 1997 (20.10.97) (30) Priority Data: 60/029,053 24 October 1996 (24.10.96) US 9624319.1 22 November 1996 (22.11.96) GB (71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): COBURN, Craig [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). KOLATAC, Christine [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). RUSH, Diane, M. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). VACCA, Joseph, P. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).</p>	<p>(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report.</p>	

(54) Title: THROMBIN INHIBITORS

(57) Abstract

A compound which inhibits human thrombin and which has structure (a) such as (b).



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

TITLE OF THE INVENTION

THROMBIN INHIBITORS

BACKGROUND OF THE INVENTION

5 Thrombin is a serine protease present in blood plasma in the form of a precursor, prothrombin. Thrombin plays a central role in the mechanism of blood coagulation by converting the solution plasma protein, fibrinogen, into insoluble fibrin.

 Edwards *et al.*, *J. Amer. Chem. Soc.* (1992) vol. 114, pp.
10 1854-63, describes peptidyl α -ketobenzoxazoles which are reversible inhibitors of the serine proteases human leukocyte elastase and porcine pancreatic elastase.

 European Publication 363 284 describes analogs of
peptidase substrates in which the nitrogen atom of the scissile amide
15 group of the substrate peptide has been replaced by hydrogen or a substituted carbonyl moiety.

 Australian Publication 86245677 also describes peptidase inhibitors having an activated electrophilic ketone moiety such as fluoromethylene ketone or α -keto carboxyl derivatives.

20 Thrombin inhibitors described in prior publications contain sidechains of arginine and lysine. These structures show low selectivity for thrombin over other trypsin-like enzymes. Some of them show toxicity of hypotension and liver toxicity.

 European Publication 601 459 describes sulfonamido
25 heterocyclic thrombin inhibitors, such as N-[4-[(aminoimino-methyl)amino]butyl]-1-[N-(2-naphthalenylsulfonyl)-L-phenylalanyl]-L-prolinamide.


 WO 94/29336 describes compounds which are useful as
thrombin inhibitors.

30 Compounds of the invention are bicyclic pyridone thrombin inhibitors. Dornow *et al.*, *Chem. Ber.*, Vol. 99, pp. 244-253 (1966) describes a procedure for making bicyclic pyridones.

- 2 -

SUMMARY OF THE INVENTION

The invention relates to compounds of the formula:



5 wherein

m is 0 or 1;

X is O or H₂;

10


R¹, R² and R³ are independently selected from the group consisting of
hydrogen,
C₁-6 alkyl-,
C₂-6 alkenyl,
15 C₂-6 alkynyl,
C₃-8 cycloalkyl-,
C₃-8cycloalkyl C₁-6alkyl-,
aryl,
aryl C₁-6 alkyl-,
20

wherein aryl is phenyl either
unsubstituted or substituted with -OH, -NH₂,
C₁-6alkyl, C₃-8cycloalkyl, or halogen;

25 or R¹ and R², along with the nitrogen atom to which R¹ is attached and
the carbon atom to which R² is attached, form a five or six-membered
saturated ring; and

- 3 -

B is




5 wherein R⁴ and R⁵ are independently selected from the group consisting of

- hydrogen,
- C₁₋₄ alkyl,
- C₂₋₄ alkenyl,
- 10 C₂₋₄ alkynyl,
- C₁₋₄ alkoxy,
- halogen,
- COOH,
- OH,
- 15 -COOR⁷, where R⁷ is C₁₋₄alkyl,
- CONR⁸R⁹, where R⁸ and R⁹ are independently
hydrogen or C₁₋₄alkyl,
- OCH₂CO₂H,
- OCH₂CO₂CH₃,
- 20 -OCH₂CO₂(CH₂)₁₋₃CH₃,
- O(CH₂)₁₋₃C(O)NR¹⁰R¹¹, wherein R¹⁰ and R¹¹ are
independently hydrogen, C₁₋₄alkyl, C₃₋₇ cycloalkyl,
or -CH₂CF₃,
- (CH₂)₁₋₄OH,
- 25 -NHC(O)CH₃,
- NHC(O)CF₃,
- NHSO₂CH₃,
- SO₂NH₂;

- 4 -

or B is

wherein R⁶ is


hydrogen,
 5 C₁-6 alkyl-,
 C₂-6 alkenyl-,
 C₂-6 alkynyl-,
 C₃-8 cycloalkyl-,
 aryl,
 10 aryl C₁-6alkyl-

wherein aryl is phenyl
 either unsubstituted or substituted with -OH,
 -NH₂, C₁-6alkyl, C₃-8 cycloalkyl, or halogen.

15

and pharmaceutically acceptable salts thereof.

A class of these compounds is



20

wherein

R¹ and R² are independently selected from the group consisting of:

25

hydrogen,


- 5 -

C₁-6alkyl,
C₃-8cycloalkylC₁-6alkyl-,
aryl C₁-6alkyl-,
wherein aryl is phenyl,

5

or R¹ and R², along with the nitrogen atom to which R¹ is attached and
the carbon atom to which R² is attached, form a five or six-membered
saturated ring; and

10 B is




wherein R⁴ and R⁵ are independently selected from the group consisting
of

15

hydrogen,
halogen,
-OCH₂C(O)NHR¹¹

20 or B is




where R⁶ is hydrogen or -CH₃,
and pharmaceutically acceptable salts thereof.

25


A group of this class of compounds is

- 6 -



wherein

- 5 R^1 and R^2 are independently selected from the group consisting of:




10

or R^1 and R^2 , along with the nitrogen atom to which R^1 is attached and the carbon atom to which R^2 is attached, form a five or six-membered saturated ring; and

15


B is




- 20 wherein R^4 and R^5 are independently selected from the group consisting of

hydrogen,
 chloro,

- 7 -



or B is



- 5 where R⁶ is hydrogen or -CH₃,
and pharmaceutically acceptable salts thereof.

10 The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. These compositions may optionally include anticoagulants, antiplatelet agents, and thrombolytic agents. The compositions can be added to blood,
15 blood products, or mammalian organs in order to effect the desired inhibitions.

The invention also includes a composition for preventing or treating unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic
20 stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels, in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. These compositions may optionally include anticoagulants, antiplatelet agents, and thrombolytic agents.

25 The invention also includes a method for reducing the thrombogenicity of a surface in a mammal by attaching to the surface, either covalently or noncovalently, a compound of the invention.

- 8 -

DETAILED DESCRIPTION OF THE INVENTION

Compounds of the present invention, which are thrombin inhibitors, are useful in anticoagulant therapy. Anticoagulant therapy is indicated for the treatment and prevention of a variety of thrombotic conditions, particularly coronary artery and cerebrovascular disease. Those experienced in this field are readily aware of the circumstances requiring anticoagulant therapy. The term "patient" used herein is taken to mean mammals such as primates, including humans, sheep, horses, cattle, pigs, dogs, cats, rats, and mice.

Thrombin inhibition is useful not only in the anticoagulant therapy of individuals having thrombotic conditions, but is useful whenever inhibition of blood coagulation is required such as to prevent coagulation of stored whole blood and to prevent coagulation in other biological samples for testing or storage. Thus, thrombin inhibitors can be added to or contacted with any medium containing or suspected of containing thrombin and in which it is desired that blood coagulation be inhibited, e.g. when contacting the mammal's blood with material selected from the group consisting of vascular grafts, stents, orthopedic prosthesis, cardiac prosthesis, and extracorporeal circulation systems

The compounds of the invention can be administered in such oral forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixers, tinctures, suspensions, syrups, and emulsions. Likewise, they may be administered in intravenous (bolus or infusion), intraperitoneal, subcutaneous, or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts. An effective but non-toxic amount of the compound desired can be employed as an anti-aggregation agent. For treating ocular build up of fibrin, the compounds may be administered intraocularly or topically as well as orally or parenterally.

The compounds can be administered in the form of a depot injection or implant preparation which may be formulated in such a manner as to permit a sustained release of the active ingredient. The active ingredient can be compressed into pellets or small cylinders and

- 9 -

implanted subcutaneously or intramuscularly as depot injections or implants. Implants may employ inert materials such as biodegradable polymers or synthetic silicones, for example, Silastic, silicone rubber or other polymers manufactured by the Dow-Corning Corporation.

5 The compounds can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.

10 The compounds may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxy-propyl-
15 methacrylamide-phenol, polyhydroxyethyl-aspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, the compounds may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and
20 polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels.

 The dosage regimen utilizing the compounds is selected in accordance with a variety of factors including type, species, age, weight,
25 sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed. An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter,
30 or arrest the progress of the condition.

 Oral dosages of the compounds, when used for the indicated effects, will range between about 0.1 mg per kg of body weight per day (mg/kg/day) to about 100 mg/kg/day and preferably 1.0-100 mg/kg/day and most preferably 1-20 mg/kg/day. Intravenously, the most preferred

- 10 -

doses will range from about 0.01 to about 10 mg/kg/minute during a constant rate infusion. Advantageously, the thrombin inhibitors may be administered in divided doses of two, three, or four times daily.

Furthermore, they can be administered in intranasal form via topical use
5 of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regime.

10 For example, oral tablets can be prepared which contain an amount of active compound of between 100 and 500 mg, e.g. 100, 200, 300, 400 or 500 mg. Typically, a patient in need of thrombin inhibitor compound, depending on weight and metabolism of the patient, would be administered between about 100 and 1000 mg active compound per
15 day. For a patient requiring 1000 mg per day, two tablets containing 250 mg of active compound can be administered in the morning and two tablets containing 250 mg of active compound can again be administered in the evening. For a patient requiring 500 mg per day, one tablet containing 250 mg of active compound can be administered in the
20 morning and one tablet containing 250 mg of active compound can again be administered in the evening.

The compounds are typically administered as active ingredients in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as "carrier"
25 materials) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixers, syrups and the like, and consistent with convention pharmaceutical practices.

For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral,
30 non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert

- 11 -

carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn-sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch methyl cellulose, agar, bentonite, xanthan gum and the like.

The compounds can also be co-administered with suitable anti-coagulation agents or thrombolytic agents such as plasminogen activators or streptokinase to achieve synergistic effects in the treatment of various ascular pathologies. For example, the compounds enhance the efficiency of tissue plasminogen activator-mediated thrombolytic reperfusion. The compounds may be administered first following thrombus formation, and tissue plasminogen activator or other plasminogen activator is administered thereafter. They may also be combined with heparin, aspirin, or warfarin.

Specific embodiments of compounds of the invention are shown in the table below. These compounds inhibit thrombin with the following potency according to *in vitro* measurements:


- 12 -

thrombin Ki (nM)


* > 1.0

** < 1.0


Structure




**



**







**



*

- 13 -

Structure	thrombin Ki (nM)
	*
	**
	**
	**

and pharmaceutically acceptable salts thereof.

- 14 -

In vitro assay for determining proteinase inhibition

Assays of human α -thrombin and human trypsin were performed at 25°C in 0.05 M TRIS buffer pH 7.4, 0.15 M NaCl, 0.1% PEG. Trypsin assays also contained 1 mM CaCl_2 .

- 5 In assays wherein rates of hydrolysis of a *p*-nitroanilide (pna) substrate were determined, a Thermomax 96-well plate reader was used to measure (at 405 nm) the time dependent appearance of *p*-nitroaniline. sar-PR-pna (sarcosine-Pro-Arg-*p*-nitroanilide) was used to assay human α -thrombin ($K_m=125 \mu\text{M}$) and human trypsin ($K_m=59$
10 μM). *p*-Nitroanilide substrate concentration was determined from measurements of absorbance at 342 nm using an extinction coefficient of $8270 \text{ cm}^{-1}\text{M}^{-1}$.

- In certain studies with potent inhibitors ($K_i < 10 \text{ nM}$) where the degree of inhibition of thrombin was high, a more sensitive
15 activity assay was employed. In this assay the rate of thrombin catalyzed hydrolysis of the fluorogenic substrate Z-GPR-afc (Cbz-Gly-Pro-Arg-7-amino-4-trifluoromethyl coumarin) ($K_m=27 \mu\text{M}$) was determined from the increase in fluorescence at 500 nm (excitation at 400 nm) associated with production of 7-amino-4-trifluoromethyl
20 coumarin. Concentrations of stock solutions of Z-GPR-afc were determined from measurements of absorbance at 380 nm of the 7-amino-4-trifluoromethyl coumarin produced upon complete hydrolysis of an aliquot of the stock solution by thrombin.

- Activity assays were performed by diluting a stock solution
25 of substrate at least tenfold to a final concentration $0.5 K_m$ into a solution containing enzyme or enzyme equilibrated with inhibitor. Times required to achieve equilibration between enzyme and inhibitor were determined in control experiments. Initial velocities of product formation in the absence (V_o) or presence of inhibitor (V_i) were
30 measured. Assuming competitive inhibition, and that unity is negligible compared $K_m/[S]$, $[I]/e$, and $[I]/e$ (where $[S]$, $[I]$, and e respectively represent the total concentrations, of substrate, inhibitor and enzyme), the equilibrium constant (K_i) for dissociation of the inhibitor from the

- 15 -

enzyme can be obtained from the dependence of V_0/V_i on $[I]$ shown in equation 1.

$$V_0/V_i = 1 + [I]/K_i \quad (1)$$

5

The activities shown by this assay indicate that the compounds of the invention are therapeutically useful for treating various conditions in patients suffering from unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial
10 fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, and reocclusion or restenosis of recanalized vessels.

Some abbreviations that may appear in this application are as follows.

15

<u>Designation</u>	
BOC (Boc)	t-butyloxycarbonyl
HBT(HOBT or HOBt)	1-hydroxybenzotriazole hydrate
BBC reagent	benzotriazolyloxy-bis(pyrrolidino)-
20 PyCIU	carbonium hexafluorophosphate
	1,1,3,3-bis(tetramethylene)-
	chlorouronium hexafluorophosphate
EDC	1-ethyl-3-(3-dimethylaminopropyl)
	carbodiimide hydrochloride
25 (BOC) ₂ O	di-t-butyl dicarbonate
DMF	dimethylformamide
Et ₃ N or TEA	triethylamine
EtOAc	ethyl acetate
TFA	trifluoroacetic acid
30 DMAP	dimethylaminopyridine
DME	dimethoxyethane
BH ₃ -THF	Borane-tetrahydrofuran complex
D-Phe(3,4-Cl ₂)	D-3,4-Dichlorophenylalanine
D-3,3-dicha	D-3,3-Dicyclohexylalanine

- 16 -

	Pro	Proline
	Arg	Arginine
	Gly	Glycine
	D-3,3,-diphe	D-3,3-Diphenylalanine
5	LAH	lithium aluminum hydroxide
	Cy	cyclohexyl
	POCl ₃	phosphorous oxychloride
	MeCN	acetonitrile
	BnEt ₃ N ⁺ Cl ⁻	benzyl triethyl ammonium chloride
10	NaH	sodium hydride
	DMF	dimethylformamide
	BrCH ₂ COO ^t Bu	tert butyl bromoacetate
	EtOH	ethyl alcohol
	Pd(C)	palladium on activated carbon catalyst
15	CF ₃ COOH	trifluoroacetic acid
	DCM	dichloromethane
	DIPEA	diisopropylethylamine

20 The compounds of the present invention may have chiral centers and occur as racemates, racemic mixtures and as individual diastereomers, or enantiomers with all isomeric forms being included in the present invention.


The term "alkyl" means straight or branched alkane containing 1 to about 10 carbon atoms, e.g., methyl, ethyl, n-propyl, 25 isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl, octyl radicals and the like. The term "alkenyl" means straight or branched alkene containing 2 to about 10 carbon atoms, e.g., propylenyl, buten-1-yl, isobutenyl, pentenylen-1-yl, 2,2-methylbuten-1-yl, 3-methylbuten-1-yl, hexen-1-yl, hepten-1-yl, and octen-1-yl radicals and the like. The term "alkynyl" means straight or branched alkyne 30 containing 2 to about 10 carbon atoms, e.g., ethynyl, propynyl, butyn-1-yl, butyn-2-yl, pentyn-1-yl, pentyn-2-yl, 3-methylbutyn-1-yl, hexyn-1-yl, hexyn-2-yl, hexyn-3-yl, 3,3-dimethylbutyn-1-yl radicals and the like. Cycloalkyl means a cyclic, saturated ring containing 3 to 8 carbon

- 17 -

atoms, e.g., cyclopropyl, cyclohexyl, etc. Halogen means chloro, bromo, fluoro or iodo.


- The pharmaceutically-acceptable salts of the compounds of the invention (in the form of water- or oil-soluble or dispersible products) include the conventional non-toxic salts or the quaternary ammonium salts which are formed, e.g., from inorganic or organic acids or bases. Examples of such acid addition salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, and undecanoate. Base salts include ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth. Also, the basic nitrogen-containing groups may be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides and others.

Compounds of the invention can be prepared according to the following general synthetic strategy:




- 18 -


is chlorinated with, for example, phosphorous oxychloride, acetonitrile and benzyltriethylammonium chloride, to form



I is then alkylated with for example, sodium hydride, dimethyl
5 formamide and *tert*-butyl bromoacetate, to form




II is subjected to Michael addition with




10

using, for example, ethyl alcohol under heated conditions, to form




- 19 -


Reductive ring closure of III using, for example, hydrogen gas and palladium on activated carbon catalyst, forms



- 5 Hydrolysis of IV with, for example, trifluoroacetic acid and dichloromethane at around 0°C, forms




Amide coupling of V with



10

(where R¹ is hydrogen or a BOC protecting group) using, for example, ethylene dichloride, 1-hydroxybenzotriazole hydrate, and diisopropylethylamine, forms

- 20 -




Where R¹ is hydrogen, VI represents the finished product. Where R¹ is BOC, VI is deprotected with hydrogen chloride and ethyl acetate to form the finished product.

- 5 Unless otherwise stated, all NMR determinations were made using 400 MHz field strength.

Intermediates used to prepare compounds of the invention were prepared as follows:

10 Preparation of L-Cyclopropylalanine Methyl Ester Hydrochloride



Step 1: N-Boc-L-2-amino-4-pentenoic acid

- To a solution of L-2-amino-4-pentenoic acid (1.15 g, 10.0 mmol) in a mixture of dioxane (10 mL) and 1N NaOH (10 mL) was stirred in an ice bath. Di-tert-butyl pyrocarbonate (2.4 g, 11.0 mmol) was added and stirring was continued for 1 h. The solution was concentrated to 10 mL and 30 mL of EtOAc was added. The solution was made acidic (pH = 3) by the addition of solid KHSO₄. The aqueous phase was extracted with EtOAc (2 x 10 mL) and dried over MgSO₄. Evaporation of the solvent afforded the N-Boc protected amino acid as a white solid.
- ¹H NMR (CDCl₃) δ 5.75 (m, 1H), 5.20 (m, 2H), 5.05 (d, J=5.0 Hz, 1H), 4.40 (d, J=5.0 Hz, 1H), 4.57 (m, 2H), 1.47 (s, 9H).

- 21 -

Step 2: N-Boc-L-cyclopropylalanine Methyl Ester

To a solution of N-Boc-L-2-amino-4-pentenoic acid (2.15 g, 10.0 mmol) in 50 mL of ether was added 100 mL of ethereal diazomethane (0.5 M, 50 mmol) by pipet. After the addition was complete, 225 mg (1.0 mmol) of Pd(OAc)₂ was added *cautiously* causing the vigorous release of N₂. Stirring was continued for 2 h. The solution was purged with argon gas, filtered through Celite and concentrated. The residue was chromatographed (1:9 EtOAc / Hexanes) to afford 2.41 g (100%) of the cyclopropanated amino ester.


¹H NMR (CDCl₃) δ 5.20 (bs, 1H), 4.43 (d, J=5.0 Hz, 1H), 3.78 (s, 3H), 1.63 (m, 2H), 1.47 (s, 9H), 0.72 (m, 1H), 0.48 (m, 2H), 0.07 (m, 2H).

Step 3: L-Cyclopropylalanine Methyl Ester

HCl gas was bubbled through a 0°C solution of N-Boc-L-Cyclopropylalanine methyl ester (2.41 g, 10.0 mmol) in 10 mL of EtOAc for 5 min. The solvent was removed *in vacuo* and the resulting solid was triturated with ether to afford the title compound.

¹H NMR (CD₃OD) δ 4.10 (t, J=7.4 Hz, 1H), 3.83 (s, 3H), 1.93 (m, 1H), 1.77 (m, 1H), 0.79 (m, 1H), 0.58 (m, 2H), 0.11 (m, 2H).

Preparation of N-Methyl-L-Cyclopropylalanine Methyl Ester Hydrochloride

Step 1: N-Boc-N-methyl-L-Cyclopropylalanine Methyl Ester

A solution of 3.5 g (14.5 mmol) of N-Boc-L-Cyclopropylalanine methyl ester from step 2 above was dissolved in 10 mL of DMF and treated with 10 mL (161.5 mmol) of methyl iodide followed by 7.0 g (30.2 mmol) of Ag₂O and the resulting mixture was heated at 55°C for 24 h. The reaction mixture was cooled, diluted with

- 22 -

20 mL of ether and filtered through a pad of Celite. The filtrate was washed with water (7 x 5 mL) and dried over MgSO₄. Evaporation of the solvent afforded 2.7 g (73%) of the title compound which was used directly in the next step without further purification.

- 5 ¹H NMR (CDCl₃, 1:1 mixture of rotomers) δ 4.80 (bs, 0.5H), 4.40 (bs 0.5H), 3.75 (s, 3H), 2.85 (s, 1.5H), 2.80 (s, 1.5H), 1.90-1.6 (m, 2H), 1.47 (s, 4.5H), 1.45 (s, 4.5H), 0.68 (m, 1H), 0.43 (m, 2H), 0.05 (m, 2H).

10 Step 2: N-Methyl-L-Cyclopropylalanine Methyl Ester

HCl gas was bubbled through a 0°C solution of N-Boc-N-Methyl-L-cyclopropylalanine methyl ester (2.7 g, 10.7 mmol) in 10 mL of EtOAc for 5 min. The solvent was removed *in vacuo* and the resulting solid was triturated with ether to afford the title compound.

- 15 ¹H NMR (CDCl₃) δ 9.80 (bs, 1H), 3.90 (s, 4H), 2.80 (s, 3H), 2.04 (m, 2H), 0.95 (m, 1H), 0.58 (m, 2H), 0.18 (m, 2H).

EXAMPLE 1



1-1

20


To a solution of 4-hydroxy-6-methyl-3-nitropyridone (Fluka, 3.15 g, 18.5 mmol) and 16.8 g (74 mmol) of BnEt₃NCl in 65 mL of MeCN was added 7.6 mL (81.4 mmol) of POCl₃. The resulting solution was stirred at 40°C for 30 min then heated at reflux for 1 h.

- 25 After evaporation of the solvent, 70 mL of water was added and the mixture was stirred at room temperature for 16 h. The precipitate which formed was filtered and washed with hexane to afford 1-1 as a yellow solid.

¹H NMR (DMSO-d₆) δ 6.45 (s, 1H), 2.25 (s, 3H).


- 30 HPLC R_f = 0.43.

- 23 -



To a 0°C solution of 4-chloro-6-methyl-3-nitropyridone 1-
1 (3.93 g, 20.8 mmol) in 80 mL of DMF was added 550 mg (22.9
5 mmol) of NaH. The resulting solution was stirred at 0°C for 15 min
then treated with 3.69 mL (25.0 mmol) of *tert*-butyl bromo acetate.
The homogeneous solution was allowed to stir to room temperature
over 16 h. After evaporation of the solvent, the residue was partitioned
between EtOAc and water. The organic phase was washed with brine,
10 dried (MgSO₄) and concentrated. Column chromatography (1:1 EtOAc
/ Hexanes) of the dark brown oil gave 1-2 as a light brown solid.
¹H NMR (CDCl₃) δ 6.21 (s, 1H), 4.75 (s, 2H), 2.35 (s, 3H), 1.45 (s,
9H).
HPLC R_f = 0.71

15




To a solution of pyridone 1-2 (401 mg, 1.32 mmol) in 6
mL of EtOH was added 239 mg (1.32 mmol) of L-cyclopropylalanine
methyl ester hydrochloride was added 0.46 mL (3.3 mmol) of Et₃N.
20 The solution was stirred at 70°C for 15 h, cooled and evaporated to an
oil. The residue was partitioned between EtOAc and water and the
organic phase was washed with brine, dried (MgSO₄) and concentrated.
Column chromatography (3:7 EtOAc / Hexanes) provided amine 1-3 as
a white solid.

- 24 -

^1H NMR (CDCl_3) δ 9.62 (d, $J=7.3$ Hz, 1H), 5.61 (s, 1H), 4.72 (d, $J=17.4$ Hz, 1H), 4.55 (d, $J=17.4$ Hz, 1H), 4.33 (q, $J=6.6$ Hz, 1H), 3.80 (s, 3H), 2.27 (s, 3H), 1.95 (m, 1H), 1.92 (m, 1H), 1.47 (s, 9H), 0.76 (m, 1H), 0.58 (m, 2H), 0.17 (m, 2H).


5 HPLC R_f = 0.69.



A solution of nitro ester 1-3 (479 mg, 1.17 mmol) and 48 mg of palladium on charcoal (10%) in 20 mL of EtOAc was hydrogenated over 30 h. The solution was filtered through Celite (EtOAc washes) and concentrated. The residue was subjected to column chromatography (2:3 EtOAc / Hexanes) to afford amine 1-4 as a white solid.

15 ^1H NMR (CDCl_3) δ 7.76 (s, 1H), 5.70 (s, 1H), 4.88 (s, 1H), 4.70 (q, $J=7.4$ Hz, 2H), 4.33 (m, 2H), 2.19 (s, 3H), 1.81 (m, 1H), 1.63 (m, 1H), 1.47 (s, 9H), 0.78 (m, 1H), 0.58 (m, 1H), 0.45 (m, 1H), 0.11 (m, 1H), 0.07 (m, 1H).

HPLC R_f = 0.58.



20


A 0°C solution of ester 1-4 (201 mg, 0.576 mmol) in 7 mL of DCM treated with 5 mL of CF_3COOH . The cold solution was stirred for 1 h and concentrated to a dark oil. The residue was azeotroped with benzene (3 x 10 mL), EtOAc (2 x 10 mL) then ether (1 x 10 mL). The

- 25 -

obtained oil was stirred with 5% MeOH in Et₂O to yield acid 1-5 as a tan solid.

¹H NMR (CD₃OD) δ 5.93 (s, 1H), 4.79 (s, 2H), 4.13 (m, 1H), 2.25 (s, 3H), 1.75 (m, 1H), 1.63 (m, 1H), 0.78 (m, 1H), 0.43 (m, 2H), 0.12 (m, 2H).

HPLC R_f = 0.41.




To a solution of carboxylic acid 1-5 (85 mg, 0.292 mmol) and 2-amino-5-aminomethyl-6-methylpyridine (120 mg, 0.876 mmol) in 2 mL of DMF was added 168 mg (0.876) of EDCI and 118 mg (0.876 mmol) of HOBt followed by 0.25 mL (1.46 mmol) of DIPEA. The homogeneous mixture was stirred at room temperature for 16 h after which time the solvent was removed under reduced pressure. The residue was subjected to column chromatography (1:9 CH₃OH / CHCl₃ sat'd with NH₃) to afford compound 1-6 as a white solid.

¹H NMR (CD₃OD) δ 7.36 (d, J=8.4 Hz, 1H), 6.39 (d, J=8.4 Hz, 1H), 5.90 (s, 1H), 4.71 (s, 2H), 4.26 (s, 2H), 4.11 (m, 1H), 2.34 (s, 3H), 2.24 (s, 3H), 1.71 (m, 1H), 1.63 (m, 1H), 0.81 (m, 1H), 0.43 (m, 2H), 0.12 (m, 2H).


HPLC R_f = 0.42.

Anal. Calc'd for C₂₁H₂₆N₆O₃·0.65 CH₂Cl₂: C; 55.83, H; 5.91, N; 18.05. Found: C; 55.85, H; 6.04, N; 17.99.

- 26 -

EXAMPLE 2

- To a solution of pyridone 1-2 (300 mg, 0.990 mmol) in 20 mL of EtOH was added 318 mg (1.38 mmol) of L-phenylalanine ethyl ester hydrochloride. To this was added 0.344 mL (2.47 mmol) of Et₃N. The solution was stirred at 70°C for 15 h, cooled and evaporated to a foam. The residue was partitioned between EtOAc and water. The organic phase was washed with brine, dried (MgSO₄) and concentrated.
- Column chromatography (95:5:1 CH₂Cl₂/CH₃OH/NH₄OH) provided amine 2-1 as a tan foam.
- ¹H NMR (CDCl₃) δ 9.62 (d, J=7.3 Hz, 1H), 7.23 (m, 5H), 5.61 (s, 1H), 4.58 (q, J=17.3 Hz, 2H), 4.47 (m, 1H), 4.12 (m, 2H), 3.23 (m, 2H), 2.18 (s, 3H), 1.45 (s, 9H), 1.23 (t, J=7.14 Hz, 3H).
- HPLC R_f = 0.74.




- A solution of nitro ester 2-1 (440 mg, 0.957 mmol) and 88 mg of palladium on charcoal (10%) in 40 mL of THF was hydrogenated over 12 h. The solution was filtered through Celite (THF washes) and concentrated. The residue was subjected to column chromatography (95:5:1 CH₂Cl₂/CH₃OH/NH₄OH) to afford amine 2-2 as a yellow solid.

- 27 -

^1H NMR (CDCl_3) δ 7.85 (s, 1H), 7.23 (m, 5H), 5.58 (s, 1H), 5.23 (s, 3H), 4.63 (m, 2H), 4.29 (m, 1H), 4.15 (m, 2H), 3.23 (m, 1H), 2.80 (m, 1H), 2.17 (s, 3H), 1.43 (s, 9H).

HPLC R_f = 0.62.


5



A 0°C solution of ester 2-2 381 mg (1.0 mmol) in 15 mL of DCM treated with 5 mL of CF_3COOH . The cold solution was stirred for 5 h and concentrated to a dark oil. The residue was azeotroped with benzene (3 x 10 mL), EtOAc (2 x 10 mL) then ether (1 x 10 mL). The obtained oil was stirred with 5% MeOH in Et_2O to yield acid 2-3 as a brown foam.

^1H NMR (CD_3OD) δ 7.22 (m, 5H), 5.93 (s, 1H), 4.79 (m, 2H), 4.13 (m, 2H), 3.12 (m, 1H), 2.20 (s, 3H).

HPLC R_f = 0.46.




To a solution of carboxylic acid 2-3 (56 mg, 0.164 mmol) and N-cyclopropyl (2-aminomethyl-5-chlorophenoxy) acetamide (71

- 28 -

mg, 0.164 mmol) in 5 mL of DMF was added 47 mg (0.247) of EDCI and 33 mg (0.247 mmol) of HOBT followed by 0.08 mL (0.574 mmol) of Et₃N. The homogeneous mixture was stirred at room temperature for 16 h after which time the solvent was removed under reduced pressure. The residue was subjected to column chromatography (95:5:0.5 CH₂Cl₂/CH₃OH/NH₄OH) to afford compound 2-4 as a tan solid.

¹H NMR (CDCl₃) δ 9.80 (bs, 1H), 8.25 (bs, 1H), 7.75 (bs, 1H), 7.37 (d, J=2.4 Hz, 1H), 7.25 (m, 5H), 7.00 (dd, J=2.4 and 8.4 Hz, 1H), 6.58 (d, J=8.4 Hz, 1H), 5.55 (s, 1H), 4.65-4.40 (m, 6H), 3.35 (d, J=1H), 2.81 (m, 1H), 2.60 (m, 1H), 2.40 (s, 3H), 0.9 (m, 3H), 0.65 (M, 2H).
HPLC R_f = 0.63.

EXAMPLE 3




To a solution of carboxylic acid 2-3 (97 mg, 0.298 mmol) and 2-amino-5-aminomethyl-6-methylpyridine (45 mg, 0.328 mmol) in 10 mL of DMF was added 79 mg (0.417) of EDCI and 56 mg (0.417 mmol) of HOBT followed by 0.20 mL (1.19 mmol) of DIPEA. The homogeneous mixture was stirred at room temperature for 16 h after which time the solvent was removed under reduced pressure. The residue was subjected to column chromatography (90:10:1 CH₂Cl₂/CH₃OH/NH₄OH) to afford compound 3-1 as a tan oil. HCl/ether was added to form the solid dihydrochloride salt.

- 29 -

¹H NMR (CD₃OD) δ 7.57 (d, J=8.4 Hz, 1H), 7.21 (m, 5H), 6.58 (d, J=8.4 Hz, 1H), 5.86 (s, 1H), 4.65 (m, 2H), 4.26 (s, 2H), 3.81 (m, 2H), 2.40 (s, 3H), 2.20 (s, 3H).
HPLC R_f = 0.45.

5


EXAMPLE 4

To a solution of pyridone 1-2 (800 mg, 2.64 mmol) in 25 mL of absolute ethanol was added L-homoproline ethyl ester (416 mg, 2.64 mmol), followed by 0.48 mL of triethylamine. The resulting solution was refluxed for 4.5 hours, then cooled to room temperature. After evaporation of the ethanol, the residue was partitioned between ethyl acetate and water. The organic phase was washed with brine, dried (MgSO₄), and concentrated to afford 4-1 as a dark yellow solid.

¹H NMR (CDCl₃) δ 5.78 (s, 1H), 4.66 (q, J=17.4 Hz, 2H), 4.22 (q, J=7.05 Hz, 2H), 3.34 (m, 2H), 2.25 (s, 3H), 2.22 (m, 1H), 1.85 (m, 1H), 1.76 (m, 1H), 1.65 (m, 2H), 1.55 (m, 2H), 1.48 (s, 9H), 1.29 (t, J=7.14 Hz, 3H).

HPLC R_f = 0.71


- 30 -



A solution of nitro ester 4-1 (1.10 g, 2.60 mmol) and 500 mg of palladium on carbon (10%) in 20 mL of EtOAc was hydrogenated at STP over 17 hours. The solution was filtered through Celite, washed with EtOAc, and concentrated to afford amine 4-2 as a solid.

^1H NMR (CDCl_3) δ 7.78 (s, 1H), 5.84 (s, 1H), 4.73 (s, 2H), 3.80 (t, $J=15.0$ Hz, 2H), 2.86 (t, $J=12.3$ Hz, 2H), 2.25 (s, 3H), 2.19 (m, 1H), 2.00 (m, 1H), 1.70 (m, 1H), 1.58 (m, 3H), 1.49 (s, 9H).

HPLC $R_f = 0.61$




A solution of ester 4-2 (700 mg, 2.02 mmol) in 3 mL of DCM at 0°C was treated with 3 mL of CF_3COOH . After stirring for 2 hours at RT, the solution was concentrated to an oil. The residue was azeotroped with toluene (6 x 20 mL) to afford acid 4-3 as a tan solid.

^1H NMR (CDCl_3) δ 8.05 (s, 1H), 5.94 (s, 1H), 4.78 (s, 2H), 3.86 (d, $J=13.55$ Hz, 2H), 2.89 (t, $J=12.6$ Hz, 1H), 2.70 (m, 1H), 2.36 (s, 3H), 2.20 (m, 1H), 2.01 (m, 1H), 1.73 (m, 1H), 1.60 (m, 3H).


HPLC $R_f = 0.45$

- 31 -




- To a solution of acid 4-3 (300 mg, 1.03 mmol) and 2-BOC-amino-5-aminomethyl-6-methylpyridine (700 mg, 3.10 mmol) in 10 mL of DMF was added HOBt (419 mg, 3.10 mmol), EDC (595 mg, 3.10 mmol), and N,N-diisopropylethyl amine (0.54 mL, 3.10 mmol). The resulting solution was stirred overnight and concentrated. The residue was redissolved in EtOAc and washed with 5% Na₂CO₃, water, and brine. The organic phase was dried (MgSO₄) and concentrated to a solid. Purification of the solid by column chromatography (8% MeOH/EtOAc), yielded 270 mg (53%) of solid. From that product 100 mg was dissolved in EtOAc at 0°C and subjected to HCl(g) for 10 min then stirred for 1 hour. The solution was concentrated to afford the final product 4-4 as a dark yellow solid.
- ¹H NMR (CD₃OD) δ 7.87 (d, J=8.97 Hz, 1H), 6.82 (d, J=9.15 Hz, 1H), 6.22 (s, 1H), 4.74 (s, 2H), 4.30 (s, 2H), 3.40 (m, 1H), 3.87 (m, 1H), 2.93 (t, J=12.91 Hz, 1H), 2.51 (s, 3H), 2.32 (s, 3H), 2.03 (m, 2H), 1.61 (m, 4H).
- HPLC R_f= 0.38

- 32 -

EXAMPLE 5

- 5 To a solution of pyridone 1-2 (500 mg, 1.65 mmol) in 15 mL of absolute ethanol was added *N*-benzyl glycine ethyl ester (320 mg, 1.65 mmol), followed by 0.30 mL of triethylamine. The resulting solution was refluxed for overnight, then cooled to room temperature. After evaporation of the ethanol *in vacuo*, the residue was partitioned
- 10 between ethyl acetate and water. The organic phase was washed with brine, dried (MgSO₄), and chromatographed (2:3 EtOAc/ Hexane) to afford 5-1 as a yellow solid.
- 15 ¹H NMR (CDCl₃) δ 7.32 (m, 5H), 5.81 (s, 1H), 4.65 (s, 2H), 4.62 (s, 2H), 4.16 (q, J=7.05 Hz, 2H), 3.87 (s, 2H), 2.20 (s, 3H), 1.47 (s, 9H), 1.25 (t, 3H).
HPLC R_f = 0.73




- 20 A solution of nitro ester 5-1 (185 mg, 0.403 mmol) and 100 mg of palladium on carbon (10%) in 10 mL of EtOAc was

- 33 -

hydrogenated at STP over 17 hours. The solution was filtered through Celite, washed with EtOAc, and concentrated to afford amine 5-2 as a solid.


¹H NMR (CDCl₃) δ 7.91 (s, 1H), 7.33 (m, 5H), 5.84 (s, 1H), 4.72(s, 2H), 4.46 (s, 2H), 3.91 (s, 2H), 2.20 (s, 3H), 1.49 (s, 9H).
HPLC R_f = 0.65



A solution of ester 5-2 (110 mg, 0.287 mmol) in 3 mL of DCM at 0°C was treated with 3 mL of CF₃COOH. The ice bath was removed and stirring was continued for 2 hours. The solution was concentrated to an oil and the resulting residue was azeotroped with toluene (6 x 20 mL) to afford acid 5-3 as a yellow solid.

¹H NMR (CD₃OD) δ 7.31 (m, 5H), 6.21 (s, 1H), 4.83 (s, 2H), 4.59(s, 2H), 3.92(s, 2H), 2.79 (s, 3H).
HPLC R_f = 0.51

- 34 -




To a solution of acid 5-3 (99.7 mg, 0.305 mmol) and 2-amino-5-aminomethyl-6-methylpyridine (6.04 mg, 0.305 mmol) in 2 mL of DMF was added HOBT (41.0 mg, 0.305 mmol), EDC (59.0 mg, 0.305 mmol), and DIPEA (106 mL, 0.609 mmol). After stirring the resulting solution overnight, it was concentrated to an oil. The crude oil was purified by crystallization with EtOAc and methanol to yield 5-4 as a light yellow solid.


¹H NMR (CD₃OD) δ 7.86 (d, J=9.16 Hz, 1H), 7.32 (m, 5H), 6.81 (d, J=9.15 Hz, 1H), 6.36 (s, 1H), 5.39 (s, 2H), 4.80 (s, 2H), 4.29 (s, 2H), 2.50 (s, 3H), 2.31 (s, 3H).

HPLC R_f= 0.48

- 35 -

EXAMPLE 6

- To a solution of pyridone 1-2 (1.00 g, 3.30 mmol) in 30 mL of absolute ethanol was added N-methyl-L-cyclopropylalanine methyl ester hydrochloride (639 mg, 3.30 mmol), followed by 1.15 mL of triethylamine. The resulting solution was refluxed for overnight, then cooled to room temperature. After evaporation of the ethanol *in vacuo*, the residue was partitioned between ethyl acetate and water.
- 10 The organic phase was washed with brine, dried (MgSO₄) to afford 6-1 as a yellow solid.
- ¹H NMR (CDCl₃) δ 5.83 (s, 1H), 4.67 (s, 2H), 4.33 (m, 1H), 3.78 (s, 3H), 2.88 (s, 3H), 2.27 (s, 3H), 2.13 (m, 1H), 1.48 (s, 9H), 1.28 (m, 1H), 0.79 (m, 1H), 0.53 (m, 2H), 0.15 (m, 2H).
- 15 HPLC R_f = 0.76




- A solution of nitro ester 6-1 (1.50 g, 3.54 mmol) and 800 mg of palladium on carbon (10%) in 30 mL of EtOAc was
- 20 hydrogenated over 48 hours. The solution was filtered through Celite, washed with EtOAc, and concentrated to afford amine 6-2 as a solid.

- 36 -

^1H NMR (CDCl_3) δ 7.82 (s, 1H), 5.76 (s, 1H), 4.73 (q, $J = 17.58$ Hz, 2H), 3.99 (t, $J = 5.31$ Hz, 1H), 3.01 (s, 3H), 2.25 (s, 3H), 1.67 (m, 2H), 1.48 (s, 9H), 0.65 (m, 1H), 0.42 (m, 2H), 0.052 (m, 2H).

HPLC $R_f = 0.65$.

5




A solution of ester 6-2 (1.0 g, 2.65 mmol) in 20 mL of DCM at 0°C was treated with 4 mL of CF_3COOH . After stirring for 4 hours at RT, the solution was concentrated to an oil. The residue was azeotroped with toluene (6 x 20 mL) to afford acid 6-3 as a tan solid.

^1H NMR (CD_3OD) δ 6.11 (s, 1H), 4.83 (s, 2H), 4.07 (t, $J = 5.04$ Hz, 1H), 3.06 (s, 3H), 2.33 (s, 3H), 1.75 (m, 1H), 1.61 (m, 1H), 0.61 (m, 1H), 0.37 (m, 2H), 0.022 (m, 2H).

HPLC $R_f = 0.4$

15



To a solution of acid 6-3 (500 mg, 1.56 mmol) and 2-BOC-amino-5-aminomethyl-6-methylpyridine (370 mg, 1.56 mmol) in 10 mL of DMF was added HOBt (210 mg, 1.56 mmol), EDC (300 mg, 1.56 mmol), and 0.54 mL of DIPEA. The resulting solution was stirred overnight and concentrated. The residue was redissolved in EtOAc and

20


- 37 -

washed with 5% Na₂CO₃, water, and brine. The organic phase was dried (MgSO₄) and concentrated to a solid. The solid was dissolved in EtOAc at 0°C and subjected to HCl(g) for 10 min then stirred for 2 hours. The solution was concentrated to a solid and purified by column chromatography (8% MeOH/ CHCl₃ (sat'd w/NH₃) to afford final product 6-4 as a light yellow solid.

¹H NMR (CD₃OD) δ 7.36 (d, J=8.42 Hz, 1H), 6.39 (d, J=8.24 Hz, 1H), 6.09 (s, 1H), 4.75 (m, 2H), 4.27 (s, 2H), 4.06 (t, J= 5.12 Hz, 1H), 3.06 (s, 3H), 2.34 (s, 3H), 2.31 (s, 3H), 1.75(m, 1H), 1.61 (m, 1H), 0.61 (m, 1H), 0.38 (m, 2H), 0.030 (m, 2H).

HPLC R_f= 0.41

EXAMPLE 7



15

7-1

To a solution of acid 6-3 (150 mg, 0.49 mmol) and 2-BOC-amino-5-aminomethyl pyridine (109 mg, 0.49 mmol) in 3 mL of DMF was added HOBt (66 mg, 0.49 mmol), EDC (93 mg, 0.49 mmol), and 0.17 ml of DIPEA. The resulting solution was stirred overnight and concentrated. The residue was redissolved in EtOAc and washed with 5% Na₂CO₃, water, and brine. The organic phase was dried (MgSO₄) and concentrated to afford 104 mg (42%) of the penultimate compound as a white solid. This was dissolved in 10 mL of a 95:5 mixture of DCM/MeOH at 0°C and subjected to HCl(g) for 10 min then stirred for 2.5 hours. The solution was concentrated to a solid and purified by column chromatography (95:5:0.5 DCM/MeOH/NH₄OH) to afford 7-1 as a light yellow solid.


- 38 -

¹H NMR (CDCl₃) δ 9.50 (bs, 1H), 8.00 (bs, 1H), 7.85 (s, 1H), 7.36 (d, J=8.4 Hz, 1H), 6.19 (d, J=8.4 Hz, 1H), 5.77 (s, 1H), 4.80 (d, J=14.8 Hz, 1H), 4.44 (m, 4H), 3.98 (dd, J= 4.0 and 14.8 Hz, 1H), 3.80 (t, J= 5.5 Hz, 1H), 3.06 (s, 3H), 2.44 (s, 3H), 1.75 (m, 2H), 1.61 (m, 2H), 0.85 (m, 1H), 0.60 (m, 1H), 0.40 (m, 2H).

HPLC R_f= 0.46

Anal. Calc'd for C₂₁H₂₆N₆O₃ • 0.2 H₂O • 0.5 EtOAc: C; 60.29, H; 6.69, N; 18.35. Found: C; 60.26, H; 6.46, N; 18.36.

10

EXAMPLE 8

To a solution of acid 6-3 (150 mg, 0.491 mmol) and N-cyclopropyl (2-aminomethylphenoxy) acetamide (108 mg, 0.491 mmol) in 3 mL of DMF was added HOBt (66 mg, 0.491 mmol), EDC (93 mg, 0.491 mmol), and 0.17 ml of DIPEA. The resulting solution was stirred overnight and concentrated. The residue was redissolved in EtOAc and washed with sat'd. NaHCO₃, water, and brine. The organic phase was dried (MgSO₄), concentrated and purified by column chromatography (1:9 MeOH/ EtOAc) to afford compound 8-1 as a white solid.

¹H NMR (CDCl₃) δ 8.99 (bs, 1H), 7.80 (bs, 1H), 7.77 (bs, 1H), 7.20 (m, 2H), 6.90 (t, J=8 Hz, 1H), 6.70 (d, J=8 Hz, 1H), 5.75 (s, 1H), 4.80-4.45 (m, 4H), 3.95 (t, 2H), 3.06 (s, 3H), 2.80 (m, 1H), 2.45 (s, 3H), 1.61 (m, 1H), 0.61 (m, 6H), 0.80 (m, 6H), 0.41 (m, 3H).

- 39 -


HPLC $R_f = 0.59$

Anal. Calc'd for $C_{27}H_{33}N_5O_5 \cdot 0.1 CH_2Cl_2$: C; 63.06, H; 6.48, N; 13.57. Found: C; 63.02, H; 6.21, N; 13.47.

5

EXAMPLE 9Tablet Preparation

Tablets containing 100.0, 200.0, and 300.0 mg, respectively, of



10

active compound are prepared as illustrated below:

<u>Ingredient</u>	<u>Amount-mg</u>		
15 Active compound	100.0	200.0	300.0
Microcrystalline cellulose	160.0	150.0	200.0
Modified food corn starch	20.0	15.0	10.0
20 Magnesium stearate	1.5	1.0	1.5

All of the active compound, cellulose, and a portion of the corn starch are mixed and granulated to 10% corn starch paste. The resulting granulation is sieved, dried and blended with the remainder of the corn starch and the magnesium stearate. The resulting granulation is then compressed into tablets containing 100.0, 200.0, and 300.0 mg, respectively, of active ingredient per tablet.

25

- 40 -

EXAMPLE 10

An intravenous dosage form of the above-indicated active compound is prepared as follows:


5	Active compound	0.5-10.0mg
	Sodium Citrate	5-50mg
10	Citric Acid	1-15mg
	Sodium Chloride	1-8mg
15	Water for Injection (USP)	q.s. to 1 L

Utilizing the above quantities, the active compound is dissolved at room temperature in a previously prepared solution of sodium chloride, citric acid, and sodium citrate in Water for Injection (USP, see page 1636 of United States Pharmacopeia/National Formulary for 1995, published by United States Pharmacopeial Convention, Inc., Rockville, Maryland, copyright 1994.

- 41 -

WHAT IS CLAIMED IS:

1. A compound having the following structure:



5

wherein

m is 0 or 1;

10 X is O or H₂;

R¹, R² and R³ are independently selected from the group consisting of
hydrogen,

15

C₁₋₆ alkyl-,C₂₋₆ alkenyl,C₂₋₆ alkynyl,C₃₋₈ cycloalkyl-C₃₋₈cycloalkyl C₁₋₆alkyl-,

aryl,

20

aryl C₁₋₆ alkyl-,

wherein aryl is phenyl either

unsubstituted or substituted with -OH, -NH₂,


C₁₋₆alkyl, C₃₋₈cycloalkyl, or halogen;

25

or R¹ and R², along with the nitrogen atom to which R¹ is attached and
the carbon atom to which R² is attached, form a five or six-membered
saturated ring; and

- 42 -

B is




wherein R⁴ and R⁵ are independently selected from the group consisting
 5 of

hydrogen,
 C₁₋₄ alkyl,
 C₂₋₄ alkenyl,
 10 C₂₋₄ alkynyl,
 C₁₋₄ alkoxy,
 halogen,
 -COOH,
 -OH,
 15 -COOR⁷, where R⁷ is C₁₋₄alkyl,
 -CONR⁸R⁹, where R⁸ and R⁹ are independently
 hydrogen or C₁₋₄alkyl,
 -OCH₂CO₂H,
 -OCH₂CO₂CH₃,
 20 -OCH₂CO₂(CH₂)₁₋₃CH₃,
 -O(CH₂)₁₋₃C(O)NR¹⁰R¹¹, wherein R¹⁰ and R¹¹ are
 independently hydrogen, C₁₋₄alkyl, C₃₋₇ cycloalkyl,
 or -CH₂CF₃,
 -(CH₂)₁₋₄OH,
 25 -NHC(O)CH₃,
 -NHC(O)CF₃,
 -NHSO₂CH₃,
 -SO₂NH₂;

- 43 -

or B is

wherein R⁶ is


hydrogen,
 5 C1-6 alkyl-,
 C2-6 alkenyl-,
 C2-6 alkynyl-,
 C3-8 cycloalkyl-,
 aryl,
 10 aryl C1-6alkyl-

wherein aryl is phenyl
 either unsubstituted or substituted with -OH,
 -NH₂, C1-6alkyl, C3-8 cycloalkyl, or halogen.

15

and pharmaceutically acceptable salts thereof.

2. The compound of claim 1 having the formula:



20

wherein

R¹ and R² are independently selected from the group consisting of:

25

hydrogen,


- 44 -

C₁-6alkyl,
 C₃-8cycloalkylC₁-6alkyl-,
 aryl C₁-6alkyl-,
 wherein aryl is phenyl,

5

or R¹ and R², along with the nitrogen atom to which R¹ is attached and the carbon atom to which R² is attached, form a five or six-membered saturated ring; and

10 B is




wherein R⁴ and R⁵ are independently selected from the group consisting of

15

hydrogen,
 halogen,
 -OCH₂C(O)NHR¹¹


20 or B is



where R⁶ is hydrogen or -CH₃,
 and pharmaceutically acceptable salts thereof.

- 45 -


3. The compound of claim 2 having the formula:



wherein

5

R¹ and R² are independently selected from the group consisting of:




10

or R¹ and R², along with the nitrogen atom to which R¹ is attached and the carbon atom to which R² is attached, form a five or six-membered saturated ring; and

15


B is




20 wherein R⁴ and R⁵ are independently selected from the group consisting of

- 46 -

hydrogen,
chloro,







5 or B is




where R⁶ is hydrogen or -CH₃,
and pharmaceutically acceptable salts thereof.

- 10 4. The compound of Claim 3 selected from the group consisting of:

- 47 -



- 48 -



and pharmaceutically acceptable salts thereof.

- 5 5. A composition for inhibiting thrombin in blood comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.

- 49 -

6. A method for inhibiting thrombin in blood in a mammal comprising administering to the mammal a composition of Claim 5.
- 5 7. A method for inhibiting formation of blood platelet aggregates in blood in a mammal comprising administering to the mammal a composition of Claim 5.
- 10 8. A method for inhibiting formation of fibrin in blood in a mammal comprising administering to the mammal a composition of Claim 5.
- 15 9. A method for inhibiting thrombus formation in blood in a mammal comprising administering to the mammal a composition of Claim 5.
10. A method for inhibiting thrombin in stored blood comprising administering to the mammal a composition of Claim 5.
- 20 11. The use of a compound of Claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for inhibiting thrombus formation, preventing thrombus formation, inhibiting thrombin, inhibiting formation of fibrin, and inhibiting formation of blood platelet aggregates, in a mammal.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/18682

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 31/395, 31/495; C07D 471/04, 471/14, 487/04, 487/14

US CL : 514/220, 221, 249, 250; 540/496, 502, 559, 568; 544/346, 350

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/220, 221, 249, 250; 540/496, 502, 559, 568; 544/346, 350

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	MACK et al. Design, synthesis and biological activity of novel rigid amidino-phenylalanine derivatives as inhibitors of thrombin. J. Enzyme Inhibition. 1995, Vol. 9, pages 73-86, especially pages 75-77.	1-11
A	EDWARDS et al. Design, synthesis and kinetic evaluation of a unique class of elastase inhibitors, the peptidyl α -ketobenzoxazoles, and the X-ray crystal structure of the covalent complex between porcine pancreatic elastase and Ac-Ala-Pro-Val-2-Benzoxazole. J. Am. Chem. Soc. 1992, Vol. 114, pages 1854-1865, especially page 1855.	1-5

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

Special categories of cited documents:	
A document defining the general state of the art which is not considered to be of particular relevance	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
B earlier document published on or after the international filing date	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y* document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
O document referring to an oral disclosure, use, exhibition or other means	*Z* document member of the same patent family
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

15 DECEMBER 1997

Date of mailing of the international search report

03 FEB 1998

 Name and mailing address of the ISA/US
 Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

EVELYN HUANG

Telephone No. (703) 308-1235

INTERNATI NAL SEARCH REPORT

International application No.
PCT/US97/18682

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BROWN et al. Design of orally active, non-peptidic inhibitors of human leukocyte elastase. J. Med. Chem. 1994, Vol. 37, pages 1259-1261, especially page 1260.	1-5
A	TEMPLE, JR. et al. Antimitotic agents: ring analogues and derivatives of ethyl [(S)-5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7 -yl] carbamate. J. Med. Chem. 1992, Vol. 35, pages 4809-4812, especially page 4809.	1-5
A	EP 0 648 780 A1 (BRISTOL-MYERS SQUIBB COMPANY) 19 April 1995, see entire document, especially page 4.	1-11